Regulus Therapeutics
RGLS
#7077
Rank
NZ$0.95 B
Marketcap
NZ$13.79
Share price
0.00%
Change (1 day)
439.77%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -NZ$79.77 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -NZ$78.08 Million a decrease over its 2023 earnings that were of -NZ$49.75 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -NZ$79.77 Million2.16%
2024 -NZ$78.08 Million56.97%
2023 -NZ$49.75 Million6.51%
2022 -NZ$46.71 Million2.53%
2021 -NZ$45.55 Million93.59%
2020 -NZ$23.53 Million-15.41%
2019 -NZ$27.82 Million-64.46%
2018 -NZ$78.26 Million-33.26%
2017 -NZ$0.12 Billion-13.98%
2016 -NZ$0.14 Billion44.77%
2015 -NZ$94.16 Million-1.63%
2014 -NZ$95.73 Million203.6%
2013 -NZ$31.53 Million8.65%
2012 -NZ$29.02 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
NZ$13.01 B-16,333.32%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
NZ$2.63 B-3,381.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$15.76 B-19,767.29%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$23.84 B-29,845.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$16.72 B-20,964.39%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-NZ$0.19 Billion 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-NZ$0.2 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
NZ$0.97 B-1,313.98%๐Ÿ‡บ๐Ÿ‡ธ USA